Latest Conatus Pharmaceuticals Inc (CNAT) Headline
Post# of 60
Posted On: 03/13/2014 6:53:22 AM
Latest Conatus Pharmaceuticals Inc (CNAT) Headlines
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
GlobeNewswire - Mon Mar 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Feb 27, 5:00AM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
Conatus Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire - Thu Feb 20, 6:00AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:
Conatus Pharmaceuticals (CNAT) Soars: Stock Rises 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:39AM CST
Conatus Pharmaceuticals Inc. was a big mover last session, as its shares rose over 19% on the day.
Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
GlobeNewswire - Mon Feb 10, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of Directors: Daniel L. Kisner, M.D., a highly respected life sciences leader with demonstrated successes in drug development, pharmaceutical and research tool approvals, and venture capital investments; and Preston S. Klassen, M.D., M.H.S., an accomplished biopharmaceutical company executive with broad experience including clinical, regulatory, medical affairs and commercial responsibilities across multiple therapeutic areas.
Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference at 1:00 p.m. ET on Monday, February 10, 2014, in New York.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Why SodaStream, Intercept Pharmaceuticals, and lululemon athletica Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jan 13, 7:30PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks didn't deliver on their bullish promise on Monday,...
Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
GlobeNewswire - Mon Jan 13, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced plans to initiate a placebo-controlled (open to sponsor) Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant (POLT) recipients. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to emricasan in late 2013 for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The trial will focus on the subset of POLT patients with reestablished liver fibrosis as a result of recurrent post-transplant hepatitis C virus infection who have successfully achieved a sustained viral response following HCV antiviral therapy (HCV-POLT).
516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely Outcome
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 10, 5:00PM CST
Sometimes it takes big news to get a biotech on investors' radar. It doesn't get much bigger than the more than 500% jump that Intercept Pharmaceuticals has had over the past two days. You're excused if you've never heard of Intercept...
Intercept Pharmaceuticals Inc: A Whole New Class of Blockbuster Drug Is Born
David Williamson, The Motley Fool - Motley Fool - Thu Jan 09, 6:43PM CST
Even in the volatile world of biotech investing, the idea of a stock instantly quadrupling in value is like a unicorn -- a mythological beast that investors never expect to actually see. Well, a unicorn just showed up today, and potentially...
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
GlobeNewswire - Wed Dec 18, 7:01AM CST
-- Live Webcast Available at 9:15 am ET --
Conatus Pharmaceuticals Inc. [CNAT] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Dec 17, 9:00AM CST
What:
Orphan Drug Status for CNAT's Emricasan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 9:30AM CST
Emricasan was awarded orphan drug status by the FDA.
Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
GlobeNewswire - Mon Dec 02, 3:01PM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.
Conatus Pharmaceuticals to Present at Piper Jaffray and Oppenheimer Healthcare Conferences in December
GlobeNewswire - Mon Nov 25, 3:05PM CST
Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in December:
Fatty Liver Disease Should Keep Stocks Moving In 2014
at Investor's Business Daily - Fri Mar 07, 4:02PM CST
One of the hottest research fields in biotech is for a disease most people have never heard of. But as data on potential treatments roll out this year, it's bound to become a lot more famous on Wall Street. Non-alcoholic steatohepatitis, or NASH,...
Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial
GlobeNewswire - Mon Mar 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH).
4 Big-Volume Stocks to Trade for Breakouts
at The Street - Thu Feb 27, 5:00AM CST
These stocks rising on unusual volume are within range of triggering breakout trades.
Conatus Pharmaceuticals to Participate in Upcoming Investor Events
GlobeNewswire - Thu Feb 20, 6:00AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled participation in the following investor events in February:
Conatus Pharmaceuticals (CNAT) Soars: Stock Rises 19.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:39AM CST
Conatus Pharmaceuticals Inc. was a big mover last session, as its shares rose over 19% on the day.
Conatus Pharmaceuticals Appoints Two Additional Independent Board Members
GlobeNewswire - Mon Feb 10, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of two additional independent members to the Conatus Board of Directors: Daniel L. Kisner, M.D., a highly respected life sciences leader with demonstrated successes in drug development, pharmaceutical and research tool approvals, and venture capital investments; and Preston S. Klassen, M.D., M.H.S., an accomplished biopharmaceutical company executive with broad experience including clinical, regulatory, medical affairs and commercial responsibilities across multiple therapeutic areas.
Conatus Pharmaceuticals to Present at BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference at 1:00 p.m. ET on Monday, February 10, 2014, in New York.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Why SodaStream, Intercept Pharmaceuticals, and lululemon athletica Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Jan 13, 7:30PM CST
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Stocks didn't deliver on their bullish promise on Monday,...
Conatus Pharmaceuticals Updates Development Strategy and 2014 Milestones
GlobeNewswire - Mon Jan 13, 6:01AM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced plans to initiate a placebo-controlled (open to sponsor) Phase 2b clinical trial in the second half of 2014 evaluating its lead drug candidate emricasan in Post Orthotopic Liver Transplant (POLT) recipients. The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to emricasan in late 2013 for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The trial will focus on the subset of POLT patients with reestablished liver fibrosis as a result of recurrent post-transplant hepatitis C virus infection who have successfully achieved a sustained viral response following HCV antiviral therapy (HCV-POLT).
516% Jump for Intercept Pharmaceuticals, Unknown Biotech With Unlikely Outcome
Brian Orelli, The Motley Fool - Motley Fool - Fri Jan 10, 5:00PM CST
Sometimes it takes big news to get a biotech on investors' radar. It doesn't get much bigger than the more than 500% jump that Intercept Pharmaceuticals has had over the past two days. You're excused if you've never heard of Intercept...
Intercept Pharmaceuticals Inc: A Whole New Class of Blockbuster Drug Is Born
David Williamson, The Motley Fool - Motley Fool - Thu Jan 09, 6:43PM CST
Even in the volatile world of biotech investing, the idea of a stock instantly quadrupling in value is like a unicorn -- a mythological beast that investors never expect to actually see. Well, a unicorn just showed up today, and potentially...
Nasdaq stocks posting largest percentage increases
AP - Thu Jan 09, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Conatus Pharmaceuticals to Ring The NASDAQ Stock Market Opening Bell in Celebration of 2013 Milestones
GlobeNewswire - Wed Dec 18, 7:01AM CST
-- Live Webcast Available at 9:15 am ET --
Conatus Pharmaceuticals Inc. [CNAT] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Tue Dec 17, 9:00AM CST
What:
Orphan Drug Status for CNAT's Emricasan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 03, 9:30AM CST
Emricasan was awarded orphan drug status by the FDA.
Conatus Pharmaceuticals Receives U.S. Orphan Drug Designation for Emricasan for Treatment of Liver Transplant Recipients With Reestablished Fibrosis
GlobeNewswire - Mon Dec 02, 3:01PM CST
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Conatus' drug candidate emricasan for the treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end-stage liver disease. The FDA's Orphan Drug Designation program is intended to encourage the development of drugs and biologics that may provide benefit to patients suffering from rare diseases or conditions.
Conatus Pharmaceuticals to Present at Piper Jaffray and Oppenheimer Healthcare Conferences in December
GlobeNewswire - Mon Nov 25, 3:05PM CST
Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present at the following upcoming conferences in December:
(0)
(0)Histogen Inc. (HSTO) Stock Research Links
Scroll down for more posts ▼